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Abstract
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as
zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effects in
vitro and in patients. We have examined the effect of fluvastatin alone and in combination with
zoledronic acid in the ATP-based tumour chemosensitivity assay (ATP-TCA) for effects on breast
and ovarian cancer tumour-derived cells. Both zoledronic acid and fluvastatin showed activity in the
ATP-TCA against breast and ovarian cancer, though fluvastatin alone was less active, particularly
against breast cancer. The combination of zoledronic acid and fluvastatin was more active than
either single agent in the ATP-TCA with some synergy against breast and ovarian cancer tumour-
derived cells. Sequential drug experiments showed that pre-treatment of ovarian tumour cells with
fluvastatin resulted in decreased sensitivity to zoledronic acid. Addition of mevalonate pathway
components with zoledronic acid with or without fluvastatin showed little effect, while mevalonate
did reduced inhibition due to fluvastatin. These data suggest that the combination of zoledronic acid
and fluvastatin may have activity against breast and ovarian cancer based on direct anti-cancer cell
effects. A clinical trial to test this is in preparation.
Background
The mevalonate pathway performs several key functions
within cells leading to the production of sterols such as
cholesterol essential to membrane formation, and to the
post-translational modification by prenylation of proteins
such as Ras and other small G proteins, which are impor-
tant second messengers of growth signals from membrane
growth factor receptors [1]. The process of prenylation
involves farnesylation and geranylgeranylation from the
mevalonate metabolite farnesyl pyrophosphate (FPP) as
shown in figure 1. While farnesylation is usually required
for translocation of Ras to the cell membrane during its
activation [2], N-Ras and K-Ras can be geranylgeranylated
in the presence of farnesyl transferase inhibitors (FTIs),
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Diagram of the mevalonate pathway Figure 1
Diagram of the mevalonate pathway. N-bisophosphonates inhibit FPP-synthase, leading to accumulation of IPP, which 
generates ApppI from AMP. ApppI has been found to be toxic to cells [19], while statins inhibit HMG-CoA reductase.
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providing a rationale for the limited clinical activity of
these agents [3,4]. Ras signalling is essential to many can-
cers, either as part of activated growth receptor pathways
or by the acquisition of activating mutations during car-
cinogenesis. There is therefore considerable interest in
inhibiting the mevalonate pathway to treat cancers.
The mevalonate pathway can be interrupted by existing
drugs at several levels. As mevalonate is synthesized from
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA),
HMG-CoA inhibitors such as the statins reduce the entry
of mevalonate into the pathway. This may explain the
observed effects of statins, normally used to lower choles-
terol levels, on the possible survival benefit in patients
with non-small cell lung cancer (NSCLC) following chem-
otherapy [5], and other effects in a wide variety of tumour
types. The newer N-bisphosphonates such as ibandronate
(Roche) and zoledronic acid (Novartis) are inhibitors of
farnesyl pyrophosphate (FPP) synthase, and therefore
reduce the amount of both FPP and GGPP available for
prenylation of Ras [6,7]. Growth inhibitory effects of
these agents have been noted in cancer cell lines and in
tumour-derived cells [7,8]. Finally, FTIs prevent the far-
nesylation of Ras and have effects in vitro on cell growth,
though their effect in cancer patients has been disappoint-
ing [9], and we have seen little effect in tumour derived
cells. This may reflect the redundancy between farnesyla-
tion and geranylgeranylation, such that inhibition of one
is insufficient to prevent the action of the other [3,4].
We have previously shown direct activity of the N-
bisphosphonate zoledronic acid in an ATP-based tumour
chemosensitivity assay (ATP-TCA) against a variety of
tumour types, including breast and ovarian cancer [8]. We
have now extended these studies to examine the effect of
fluvastatin alone and in combination with zoledronic
acid against ovarian and breast cancer in vitro.
Methods
Tumour samples
A total of 31 tumours were tested in this study, comprising
of 9 primary breast and 22 pre-treated (mostly with plati-
num based chemotherapy) ovarian carcinomas. The
median age was 50 (range 41–78) and 58 (range 33–86)
respectively. Samples were obtained from laboratories
located in Germany and the UK. In each case only tissue
surplus to diagnostic requirements was used for research,
in accordance with local research ethics committee
approval. All patients gave informed consent for the
research use of their tissue.
Drugs
Zoledronic acid (hydrated sodium salt) was obtained
from Novartis (Basel, Switzerland), and fluvastatin
(344095-25) was obtained from VWR International
(Leicestershire, UK). Both drugs were diluted in complete
assay media (CAM) to concentrations thought to be
achievable clinically. Zoledronic acid was tested at 2.2 –
69.0 μM (100% test drug concentration, TDC = 34.5 μM).
Fluvastatin was tested at two concentration ranges: A = 0.1
– 2.7 μM (100% TDC = 1.4 μM) and B = 0.7 – 23.0 μM
(100% TDC = 11.5 μM) in the German and Portsmouth
laboratories respectively. Combinations of zoledronic
acid and fluvastatin were tested by simultaneous addition.
ATP-TCA
The ATP-TCA was performed as previously described
[8,10,11]. Briefly, tumour cells were dissociated from
solid tumour by collagenase (Sigma; C8051) digestion
and extracted either from the resulting cell suspension, or
directly from ascites, by density centrifugation over Ficoll
(Sigma; 1077-1). Cells were re-suspended in serum-free
CAM (DCS Innovative Diagnostik Systeme, Hamburg,
Germany) and plated in 96-well polypropylene plates
(Corning Life Sciences, High Wycombe, UK) at 20,000
solid tumour-derived or 10,000 ascites-derived cells per
well in 100 μl CAM.
Drugs were added in a further 100 μl to triplicate wells at
serial dilutions corresponding to 6.25–200% of a clini-
cally achievable test drug concentration (TDC) estimated
from pharmacokinetic data, including the degree of pro-
tein binding [10]. Each plate contained two rows of con-
trol wells: one contained medium-only (MO), while the
other contained a maximum inhibitor (MI) control which
kills all cells present. The plates were incubated for 6 days
at 37°C, with 5% CO2 and 99% humidity. At the end of
the incubation period, cells were lysed by addition of cell
extraction reagent (DCS Innovative Diagnostik Systeme).
A 50 μl aliquot of the lysate from each well was added to
the corresponding wells of a white 96-well microplate
(Thermo Life Sciences, Basingstoke, UK), followed by
addition of 50 μl luciferin-luciferase reagent. Light output
is directly proportional to the amount of ATP present and
was measured in a luminometer (MPLX; Berthold Detec-
tion Systems, Hamburg, Germany). The percentage inhi-
bition at each of the six drug concentrations tested was
calculated in relation to controls as: (1 - (test-MI)/(MO-
MI))*100. The IC50 and IC90 were calculated by the trap-
ezoidal rule, and a natural logarithmic sum index (Index-
SUM) was obtained by direct addition of the percentage
survival at each concentration tested (IndexSUM = 600-Σ
(%Inhibition6.25...200) as this has been shown to provide a
better indication of sensitivity or resistance to different
drugs in different tumour types than other ATP-TCA
parameters [12]. Total inhibition results in an IndexSUM of
0 (sensitivity), while no inhibition at any concentration
produces an index of 600 (resistance).BMC Cancer 2009, 9:38 http://www.biomedcentral.com/1471-2407/9/38
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Data analysis
The ATP-TCA results were entered into an ACCESS (Micro-
soft) database for further analysis. Statistical tests were
performed using non-parametric methods. Additive or
synergistic effects were assessed using the methods
described by Poch et al., [13]. When synergy was indicated
by the Poch method, Chou & Talalay [14] analysis was
used to evaluate combinational effects. The combina-
tional indicies (CI) at 50% and 90% were calculated in the
following way:
CIA+B = [(DA/A+B)/DA]+ [(DB/A+B)/DB]+ [α(DA/A+B)/DADB]
Where CIA+B = CI for fixed effect (F = 50% or 90%) for the
combination of cytotoxic A and cytotoxic B; DA/A+B = con-
centration of cytotoxic A in the combination A+B giving
an effect F; DB/A+B = concentration of cytotoxic B in the
combination A+B giving an effect F; DA = concentration of
cytotoxic A alone giving an effect F; DB = concentration of
cytotoxic B alone giving an effect F. α = parameter with
value 0 when A and B are mutually exclusive and 1 when
A and B are mutually non-exclusive. The CI index indi-
cated synergism <0.8; additivity >0.8 and <1.2 and antag-
onism >1.2 [15].
Sequential studies
Ovarian tumour derived cell suspensions were added to
round-bottomed polypropylene 96-well plates prepared
with 100 μl CAM pre-conditioned with either fluvastatin
(2.9 μM) or zoledronic acid (8.6 μM). The corresponding
drug plates were prepared with CAM and single agent flu-
vastatin or zoledronic acid at six dilutions (6.25–200%)
of the test drug concentration in triplicate. Each plate
included two internal controls (MI and MO). Both the cell
plates and the drug plates were incubated at 37°C in 5%
CO2 for 24 hours. Following pre-incubation, cells were
pelleted via centrifugation and the media discarded. The
contents of the fluvastatin drug plate were transferred to
the zoledronic acid pre-conditioned cells and the contents
of the zoledronic acid drug plate were transferred to the
fluvastatin pre-conditioned cells. The cell suspensions
were gently mixed. The plates containing both cells and
drugs at six dilutions were incubated for a further 5 days
at 37°C in 5% CO2. After the 5 day incubation the cells
were lysed and the ATP concentration measured as
described previously. The results were assessed as previ-
ously described and compared to the ATP-TCA single
agent results for each drug.
Substrate replacement studies
Substrate replacement experiments were conducted using
Farnesyl diphosphate (FPP; Echelon Biosciences Inc, Salt
Lake City, UT, USA), Mevalonate (Sigma Chemical Co
Ltd, Poole, UK), Farnesol (Sigma), and Geranylgeraniol
(Sigma) by simultaneous addition, or pre-incubation
using a static concentration or double dilution as indi-
cated in the results section.
Results
Effect of single agents
Both zoledronic acid and fluvastatin showed inhibition in
the ATP-TCA at all concentrations tested. Zoledronic acid
showed greater activity than fluvastatin with lower
median IndexSUM values in all tumours (table 1). Both
agents showed a shallow rise in their activity with increas-
ing concentration (figure 2a–c). The degree of inhibition
attained by zoledronic acid for breast and ovarian cancer
was similar, but fluvastatin appears to be less active
against breast cancer in the ATP-TCA in comparison with
ovarian tumour samples.
Effect of combination
The combination of zoledronic acid and fluvastatin
showed considerable activity against breast and ovarian
cancer. A total of 56% (5/9) breast and 50% (11/22) of
ovarian tumours achieved >95% inhibition at clinically
achievable concentrations. Figure 3a demonstrates that
the combination of zoledronic acid and fluvastatin exhib-
ited synergy in breast samples when the lower concentra-
tion of fluvastatin was used (0.1–2.7 μM). In the ovarian
samples there was synergy at the lower concentrations
(figure 3b) when the lower concentration of fluvastatin
was used compared to the higher fluvastatin concentra-
tion range where the difference between the independent
action and the combination result was negligible (figure
3c). Where there were IC50 and IC90 values available the
CI50 and CI90 values were calculated for each sample
using the Chou & Talalay [14] method. For the breast
samples the CI50 and CI90 values indicated that, 89% (8/
9) and 78% (7/9) showed synergism, 11% (1/9) and 11%
(1/9) showed additivity. No samples had a CI50 that indi-
cated antagonism but for the CI90, 1 sample showed
antagonism. The median CI50 and CI90 values were 0.6
(synergy) and 0.6 (synergy) respectively. For the ovarian
samples treated with the lower fluvastatin concentration,
the CI50 and CI90 values indicated that 57% (4/7) and
57% (4/7) showed synergism, no samples had a CI50 that
indicated additivity but for the CI90, 1 sample showed
additivity, and 43% (3/7) and 14% (1/7) showed antago-
nism. The median CI50 and CI90 values were 0.8 (syn-
ergy) and 0.6 (synergy) respectively. For the ovarian
samples treated with the higher fluvastatin concentration,
the CI50 and CI90 values indicated that 46% (6/13) and
69% (9/13) showed synergism, 23% (3/13) and 15% (2/
13) showed additivity and 31% (4/13) and 15% (2/13)
showed antagonism. The median CI50 and CI90 values
were 0.9 (additivity) and 0.5 (synergy) respectively.BMC Cancer 2009, 9:38 http://www.biomedcentral.com/1471-2407/9/38
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Median inhibition by zoledronic acid and fluvastatin alone and in combination in a) breast carcinomas tested with fluvastatin  concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A (n = 8) and c) ovarian carcinomas tested  with fluvastatin concentration B (n = 14) Figure 2
Median inhibition by zoledronic acid and fluvastatin alone and in combination in a) breast carcinomas tested 
with fluvastatin concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A (n = 8) 
and c) ovarian carcinomas tested with fluvastatin concentration B (n = 14). The combination results are expressed 
as micromolar concentrations of zoledronic acid.
a) 
0
20
40
60
80
100
2.2 4.3 8.6 17.3 34.5 69.0
Zoledronic acid concentration (microM)
I
n
h
i
b
i
t
i
o
n
 
%
0.1 0.2 0.3 0.7 1.4 2.7
Fluvastatin concentration (microM)
Zoledronic acid Fluvastatin Zoledroninc acid + Fluvastatin
          
b) 
0
20
40
60
80
100
2.2 4.3 8.6 17.3 34.5 69.0
Zoledronic acid concentration (microM)
I
n
h
i
b
i
t
i
o
n
 
%
0.1 0.2 0.3 0.7 1.4 2.7
Fluvastatin concentration (microM)
Zoledronic acid Fluvastatin Zoledroninc acid + Fluvastatin
 
c) 
0
20
40
60
80
100
2.2 4.3 8.6 17.3 34.5 69.0
Zoledronic acid concentration (microM)
I
n
h
i
b
i
t
i
o
n
 
%
0.7 1.4 2.9 5.8 11.5 23.0
Fluvastatin concentration (microM)
Zoledronic acid Fluvastatin Zoledroninc acid + FluvastatinBMC Cancer 2009, 9:38 http://www.biomedcentral.com/1471-2407/9/38
Page 6 of 10
(page number not for citation purposes)
Median combination analysis showing synergy between zoledronic acid plus fluvastatin in a) breast carcinomas tested with fluv- astatin concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A (n = 8) and c) ovarian carcino- mas tested with fluvastatin concentration B (n = 14) Figure 3
Median combination analysis showing synergy between zoledronic acid plus fluvastatin in a) breast carcinomas 
tested with fluvastatin concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A 
(n = 8) and c) ovarian carcinomas tested with fluvastatin concentration B (n = 14).
a) 
0
20
40
60
80
100
0.1 0.2 0.3 0.7 1.4 2.7
Fluvastatin concentration (microM)
I
n
h
i
b
i
t
i
o
n
 
%
2.2 4.3 8.6 17.3 34.5 69.0
Zoledronic acid concentration (microM)
Independent Action Combination Result
 
b) 
0
20
40
60
80
100
0.1 0.2 0.3 0.7 1.4 2.7
Fluvastatin concentration (microM)
I
n
h
i
b
i
t
i
o
n
 
%
2.2 4.3 8.6 17.3 34.5 69.0
Zoledronic acid concentration (microM)
Independent Action Combination Result
c) 
0
20
40
60
80
100
0.7 1.4 2.9 5.8 11.5 23.0
Fluvastatin concentration (microM)
I
n
h
i
b
i
t
i
o
n
 
%
2.2 4.3 8.6 17.3 34.5 69.0
Zoledronic acid concentration (microM)
Independent Action Combination ResultBMC Cancer 2009, 9:38 http://www.biomedcentral.com/1471-2407/9/38
Page 7 of 10
(page number not for citation purposes)
Sequential effects
The sequential drug experiments show that ovarian
tumour cells exposed to fluvastatin exhibit little or no dif-
ferences in their sensitivity to fluvastatin regardless of
whether they have been pre-exposed to zoledronic acid or
not (figure 4a). However, in comparison ovarian tumour
cells treated with zoledronic acid have a decreased sensi-
tivity to the drug if they have been pre-exposed to fluvas-
tatin (figure 4b). All 5 samples tested with zoledronic acid
following pre-exposure to fluvastatin exhibited an
increase in their IndexSUM value compared to cells that had
not been pre-exposed to fluvastatin.
Substrate replacement studies
Experiments were conducted with a single primary ovar-
ian cancer from which large numbers of cells were
obtained, allowing a many different experiments to be
performed. The effect of mevalonate (5, 200, 1537 μM),
geranylgeraniol (10 μM), farnesol (10 μM) and farnesyl
diphosphate (FPP, 23 μM) alone on these cells showed no
evidence of toxicity. Replacement and pre-incubation
experiments (3 and 24 hours) were performed with
zoledronic acid and fluvastatin (figure 5). Whereas fluvas-
tatin activity showed reversal by increasing mevalonate
concentration, this had little effect on downstream inhibi-
tion by zoledronic acid alone or the combination of
zoledronic acid + fluvastatin. FPP addition reversed only
weakly the effects of fluvastatin (figure 5), and showed
minor reversal of the activity of zoledronic acid and
zoledronic acid + fluvastatin. Addition of geranylgeraniol
and farnesol showed no effects (figure 5). Subsequent
experiments were conducted with FPP and mevalonate in
two further ovarian cancers, with no effect (data not
shown).
Discussion
The ATP-TCA data show convincing inhibition by both
single agents, similar in the case of zoledronic acid to that
seen previously [8]. The degree of inhibition by fluvasta-
tin is lower in breast cancer than ovarian cancer cells.
Combination of the two drugs is even more effective than
zoledronic acid alone and analysis using the Poch et al.,
[13] method indicates that fluvastatin may be more effec-
tive when used at a lower concentration. Calculation of
the CI50 and CI90 using the Chou & Talalay [14] method
demonstrated that there was synergism when zoledronic
acid was combined with fluvastatin. Similar data have
recently been reported in cell lines by Budman & Calabro
[16], showing that the combination of zoledronic acid
and fluvastatin is more cytotoxic than either drug alone,
and also in myeloma cell lines [17]. However, cell lines
can be misleading and it is prudent to examine effects in
tumour-derived cells whenever possible [18].
The underlying mechanism for the activity of zoledronic
acid and fluvastatin against cancer cells has been sug-
gested to involve Ras prenylation, which is affected by
both agents. The combination would be expected to pro-
duce an enhanced effect. Preliminary experiments per-
formed by our collaborators have shown inhibition of
prenylation of Rap1a in MCF7 cells treated with the single
agents (M Rogers, personal communication). Is this is cor-
rect, then given before the bisphosphonate, statins would
be expected to block entry of mevalonate into the pathway
reducing the substrate concentration for the step blocked
by zoledronic acid and hence increasing the efficacy of the
combination. The sequential data are therefore interesting
as they appear to be at variance with this model, and sug-
gest instead that statins are more effective when given after
zoledronic acid. This could result from an alternative
mechanism.
It has recently been suggested that the generation of an
unusual metabolite of ATP, known as ApppI from IPP
(figure 1), may be responsible for some of the toxic effects
of the N-bisphosphonates [19,20]. If this is the case,
greater activity would be expected if the zoledronic acid
was given first, followed by the statin to prevent the entry
of further mevalonate into the pathway diluting the effect
of the ApppI and allowing new pools of FPP to be pro-
duced. This explanation is supported by our replacement
substrate experiments. In these, mevalonate was able to
reverse fluvastatin effects almost completely (at high
mevalonate concentrations), while it had no effect on the
downstream inhibitor, zoledronic acid. FPP is down-
stream of the block created by zoledronic acid, but was
unable to reverse the zoledronic acid effect, consistent
with greater importance of the alternate ApppI mecha-
nism.
Both zoledronic acid and fluvastatin are well tolerated.
Indeed, it is likely that a number of patients have been
treated with both agents by accident, since the former is
indicated for breast cancer patients with metastases and
statins are commonly prescribed as cholesterol lowering
agents in patients with concomitant ischaemic heart dis-
ease. We have been unable to find any evidence of a toxic
interaction between N-bisphosphonates and statins in the
literature. Zoledronic acid is rapidly excreted by the kid-
ney and has a short half-life such that after a single dose,
none is detectable in plasma after 24 hours [21,22]. In
human and animal studies, concentrations in bone are
around 10 times those in bone marrow, which is in turn
in 10 times those in peripheral tissues, where concentra-
tions within the range tested here have been noted after
single doses in animals (Novartis – data on file). No
human data are available for ascitic fluid or breast tumour
tissue, but it is likely that the concentrations used here are
active, particularly as the length of exposure will be higherBMC Cancer 2009, 9:38 http://www.biomedcentral.com/1471-2407/9/38
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Schedule dependence of effect of zoledronic acid and fluvastatin compared to singe agent treatment in ovarian tumour derived  cells Figure 4
Schedule dependence of effect of zoledronic acid and fluvastatin compared to singe agent treatment in ovarian 
tumour derived cells. Cells were pre-conditioned for 24 hours with a) zoledronic acid or b) fluvastatin and then incubated 
for 5 days with fluvastatin or zoledronic acid respectively.
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in patients than the assay, which exposes cells to drugs for
just 6 days.
The direct effects of zoledronic acid against tumours have
also been attributed to immunological effects on γδT-lym-
phocytes [23] and to effects on angiogenesis [24]. Both
effects are of course unlikely within the ATP-TCA as lym-
phocytes are killed by the selective medium and angiogen-
esis is not required by cells in culture. Nevertheless, these
remain intriguing effects of these drugs and may augment
the direct effects on cancer cells seen here and in our pre-
vious paper [8]. The combination of these effects may be
clinically useful [25], and there is increasing evidence of
an effect of zoledronic acid against tumour cells including
a recently reported randomised controlled trial in breast
cancer [26].
Conclusion
This study shows that the combination of zoledronic acid
and fluvastatin exhibits synergy in breast and ovarian
tumour derived cells and that it may have activity against
breast and ovarian cancer. A phase II clinical trial is now
in preparation.
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concentrations (5, 200, and 1537 μM respectively), geranylgeraniol (GG, 10 μM) and farnesyl diphosphate 
(FPP, 23 μM) on zoledronic acid (ZA) and fluvastatin (Fluva) activity in a recurrent ovarian cancer.
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